Alliance A041701 (Acute Myeloid Leukemia)

What is the Purpose of this Study?

If you join this study, you will:
- Be randomly assigned (50/50 chance, like flipping a coin) to either Group 1 or Group 2
-- Group 1 will get treatment with chemotherapy drugs (daunorubicin + cytarabine)
-- Group 2 will get treatment with chemotherapy drugs (daunorubicin + cytarabine) in addition to the study drug uproleselan
- Have blood draws
- Have a bone marrow sample taken
- Have scans to get images of your heart (echocardiogram)
- Receive the chemotherapy and study drug through a vein in your arm (IV)
What is the Condition Being Studied?
Acute Myeloid Leukemia (AML)

Who Can Participate in this Study?

Adults ages 60 and older who:

- Are diagnosed with AML

- Do not have a genetic defect in a receptor called FMS-like Tyrosine Kinase 3/FLT3

- Have not received chemotherapy

- Have no signs of brain or spinal cord involvement

Age Group
Adults
Participating Institutions

What is Involved?

We are doing this study to find out how an experimental drug called uproleselan works in your body and against your cancer.

Study Details

Full Title
Alliance A041701: A Randomized Phase II/III Study of Conventional Chemotherapy +/- Uproleselan (GMI-1271) in Older Adults with Acute Myeloid Leukemia Receiving Intensive Induction Chemotherapy
Principal Investigator
Harry Erba
Instructor in the Department of Medicine

Protocol Number
IRB:
PRO00102302

NCT:
NCT03701308
ClinicalTrials.gov
View on ClinicalTrials.gov